ApoGlyx closes 6 million SEK financing round

The Board of Directors of Flerie and the Board of Directors of Toleranzia have adopted a plan to join forces through a statutory merger between the companies in accordance with the Swedish Companies Act.

Novo Nordisk and the United Laboratories International Holdings Limited (TUL)'s wholly-owned subsidiary The United Bio-Technology have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.

AstraZeneca is establishing a new global strategic R&D centre in Beijing, its second in China and sixth worldwide.

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HLX22 (AC101), an anti-HER2 monoclonal antibody, for the treatment of gastric cancer.

Xbrane Biopharma has entered into an agreement to sell XB003 (biosimilar candidate to Cimzia) and parts of its organization, including approximately 40 employees and laboratory equipment, to Alvotech for a total consideration of approximately SEK 275 million.

The FDA has approved the company’s IND application to initiate the Phase I/II study Oncorella-1.

The US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need.